Logo image
Back
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Journal article   Peer reviewed

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Lainie P Martin, Michael Sill, Mark S Shahin, Matthew Powell, Paul DiSilvestro, Lisa M Landrum, Stephanie L Gaillard, Michael J Goodheart, James Hoffman and Russell J Schilder
Gynecologic Oncology, Vol.132(3), pp.526-530
03/2014
DOI: 10.1016/j.ygyno.2013.12.018
PMCID: PMC4469031
PMID: 24361733
url
http://doi.org/10.1016/j.ygyno.2013.12.018View
Open Access

Abstract

This open-label, multi-institutional phase II trial evaluated activity and safety of rilotumumab (AMG 102), a monoclonal antibody that targets HGF (hepatocyte growth factor), the ligand for the MET receptor, in women with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Women were eligible for treatment with rilotumumab if they had measurable disease, a performance status of 0, 1 or 2, previously received platinum-based therapy with a progression-free interval of <12months or a second recurrence, and adequate bone marrow and organ function. Patients received rilotumumab 20mg/kg IV every 14days until evidence of unacceptable toxicity or disease progression. The study utilized co-dual primary endpoints of tumor response and six-month PFS to assess the efficacy of rilotumumab. Secondary endpoints included the frequency and severity of adverse events and the duration of progression-free and overall survival. Thirty-one women enrolled and received rilotumumab. All were eligible for analysis. One patient achieved a complete response (3.2%; 90% CI 0.2–14%), and two women had 6-month PFS (6.5%; 90% CI 1.1–19%). Most adverse events were grade 1 or 2, with no grade 4 adverse events. Grade 3 adverse events were gastrointestinal (4), metabolic (3) anemia (3), a thromboembolic event (1), ventricular tachycardia (1), hypotension during infusion (1) and fatigue (1). The study was stopped after the first stage of accrual. Rilotumumab was well-tolerated, but had limited activity. The level of activity does not warrant further evaluation of rilotumumab as a single agent in patients with ovarian cancer. •Rilotumumab is a monoclonal antibody targeting hepatocyte growth factor/scatter factor (HGF/SF), the ligand for the MET receptor.•Rilotumumab is the first agent targeting the MET pathway to be tested in women with epithelial ovarian cancer.•Rilotumumab (AMG 102) is well tolerated with limited single agent activity in patients with ovarian cancer.
 OVARIAN CANCER Clinical trial Rilotumumab MET AMG 102 Scatter factor HGF

Details

Metrics

45 Record Views
33 Times Cited - Web of Science
Logo image